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hemofilter, thus reducing the inactivation of transfused
platelets. Abciximab does have a high affinity (KD) for gly-
coprotein IIb/IIIa; however, as this is a reversible binding,
removing the free abciximab will shift the equilibrium,
reducing the degree of platelet inhibition. Interpretation of
KD values can be misleading since the degree of binding is
not necessarily correlated with physiologic platelet inhibi-
tion that results, and the KD value can overestimate the bind-
ing activity caused by methodologic calcium ion artifacts.3
The binding of abciximab to the α
v
β3 receptor found on
endothelium and smooth muscle cells plays no role with
regard to hemostasis. However, the interaction may be very
beneficial from an anti-inflammatory, ischemia-reperfusion
perspective.
Third, with a half-life of about 30 minutes, free abciximab
will still be present at a sufficient concentration to inactivate
platelets 90 minutes after bolus administration. Obviously the
free concentration will be substantially higher if the abcix-
imab has been administered as a bolus followed by an infu-
sion (10 µg/min).
Fourth, the statement that no unbound molecules of abcix-
imab are available is untrue. This free pool is the source of
abciximab that inactivates transfused platelets,2 since
platelet-to-platelet transfer to abciximab is unlikely to occur
(this is microaggregation, which abciximab inhibits). In fact,
abciximab is administered as an infusion for the sole purpose
of maintaining a steady free plasma concentration of abcix-
imab to maintain platelet inhibition.2-4
Fifth, the series of Booth, Lincoff, and others5 provides
additional evidence that abciximab is associated with
increased bleeding, since a higher rate of blood transfusion
was required unless platelets were administered prophylacti-
cally. Only with some form of preoperative platelet function
testing is it valid to use anecdotal evidence of success or fail-
ure of operating on patients who have received abciximab
without any excessive bleeding. Unfortunately, because of
space limitations, the information in their abstract does not
specify the degree of platelet inhibition present in their
patients preoperatively, since it is well known that abciximab
has a variable clinical effect. Whole blood microaggregation
provides a quick, simple test of platelet inhibition caused by
abciximab, and it does not involve custom-made equipment
or conventional platelet function tests, which are impractical
in an emergency.6
A trial involving patients is the only answer to the possible
use of a hemoconcentrator after abciximab administration.
However, preoperative platelet function caused by abciximab
administration, time since administration, and patient
weight—all known risk factors—should be included, factors
not present in any publications so far.
A point of importance not raised by Steinhubl, Moore,
and Lincoff, however, is the concomitant administration of
other antiplatelet agents. Clopidogrel/ticlopidine and
aspirin are frequently combined in various regimens with
abciximab. Hemofiltration should have no effect on the out-
come of such complete and permanent blockage of platelet
function that is almost certainly present with such a combi-
nation.
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Transcutaneous extracorporeal cannulation for
bilateral lung transplantation without splitting the
sternum
To the Editor:
Bilateral sequential lung transplantation without sternal
division has recently been recommended as a less-invasive
approach than sternotomy.1,2 Two separate bilateral anterolat-
eral thoracotomies in selected patients eliminate post-trans-
plantation sternal complications and improve functional
recovery. Actually, this is our routine approach for bilateral
lung transplantation.
When cardiopulmonary bypass (CPB) is electively or
urgently required during the procedure, we use two differ-
ent approaches. Cannulation of the aorta and right atrium
can be done through a right thoracotomy or transcutaneous-
ly in the 3rd and 4th intercostal spaces. We report the case
of a patient requiring elective CPB in a bilateral lung trans-
plantation setting.
Clinical summary. A 49-year-old man with α1-antitrypsin
emphysema and secondary pulmonary hypertension (systolic
pulmonary artery pressure 80 mm Hg) was accepted for bilat-
eral lung transplantation. When a donor became available, we
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decided to use two sequential anterolateral thoracotomies and
elective CPB.
After dissection of the right hilar structures, the aortic can-
nula (Stöckert 5.2 mm, Munich, Germany) was introduced
through the skin and right 3rd parasternal intercostal space.
The cannula was later used for apical chest tube drainage (Fig
1). The single 2-stage venous cannula (Bard 46F-34F, C.R.
Bard, Inc, Haverhill, Mass) was introduced through the skin
and right 4th parasternal intercostal space, just in front of the
right atrial appendage.
This particular case involved a long-distance procurement
with an ischemic time of 4 hours 10 minutes on arrival at our
institution. When CPB was instituted and right pneumonecto-
my followed by lung implantation was performed, the ischemic
time was 6 hours 15 minutes). The left lung was transplanted
sequentially, with an ischemic time of 7 hours 25 minutes. The
total CPB time was 3 hours 15 minutes. The first PO2 reading
with 100% inspired oxygen fraction was 520 mm Hg.
Recovery was uneventful, without ischemia-reperfusion injury.
Discussion. There is no doubt that a smaller incision pro-
duces less trauma and less pain, reduces the risk of wound
complications, and facilitates recovery. On the other hand, the
minimally invasive approaches have the disadvantage of pro-
ducing a smaller surgical field. The majority of bilateral lung
transplantations have been performed through an anterolater-
al thoracosternotomy known as the “clamshell” incision.3-5
The introduction of a less invasive incision, the two sequen-
tial anterolateral thoracotomies, has the challenge of per-
forming the conventional lung transplantation through a min-
imally invasive approach.
When CPB is necessary, the surgeon faces the challenge of
finding a way to perform cannulation with the same type of
cannulas and without increasing the size of the small incision.
Femoral cannulation may be an alternative but is associated
with important vascular complications.
The transcutaneous extracorporeal cannulation technique
herein described is very helpful in these patients. The cannu-
las are left in place away from the thoracotomy opening and
provide adequate drainage of the ventricles without hamper-
ing the operation. Furthermore, exposure of the hilar struc-
tures is greatly improved, and the course of the procedure
may progress smoothly without increasing the skin incision. 
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Cardiac aspergillosis
To the Editor:
Although nosocomial infection is decreasing in Spanish
hospitals,1 a relative increase in infections caused by fungi is
Fig 1. Right anterior thoracotomy showing cannulation of the
aorta (small arrow) and right atrial appendage (large arrow). 
Fig 2. Transcutaneous approach for cannulation in right ante-
rior thoracotomy (arrow). No sternal split is necessary.
